



**RESPONSE UNDER 37 C.F.R. §1.116**  
**EXPEDITED PROCEDURE**  
**GROUP ART UNIT 1644**

Dkt. 30852.13USD1/SBA/HVR

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Richard Harkins et al.  
Serial No. : 10/616,279 Examiner: Michael E. Szperka, Ph.D.  
Filed : July 8, 2003 Group Art Unit: 1644  
Title : DNA ENCODING A NOVEL RG1 POLYPEPTIDE

55 S. Lake Avenue, Suite 710  
Pasadena, CA 91101  
May 7, 2007

MAIL STOP AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT IN RESPONSE**  
**TO THE FEBRUARY 8, 2007 OFFICE ACTION**

This Amendment is being submitted in response to the Office Action dated February 8, 2007 issued by the U.S. Patent and Trademark Office in connection with the above-identified application. A response to the Office Action is due May 8, 2007. Accordingly, this Amendment is being timely filed.

radioisotopes.

48. (PREVIOUSLY PRESENTED) The method of claim 35, wherein the antibody fragment is selected from the group consisting of Fv fragments, F(ab') fragments, single chain antibodies and F(ab')<sub>2</sub> fragments.
49. (CANCELLED)
50. (PREVIOUSLY PRESENTED) The method of claim 35, wherein the antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a humanized antibody and a fully-human antibody.
51. (CURRENTLY AMENDED) The method of claim 47, wherein the radioisotope is selected from the group consisting of <sup>46</sup>Sc, <sup>47</sup>Se, <sup>48</sup>Se, <sup>72</sup>Ga, <sup>73</sup>Ga, <sup>90</sup>Y, <sup>67</sup>Cu, <sup>109</sup>Pd, <sup>111</sup>Ag, <sup>149</sup>Pm, <sup>153</sup>Sm, <sup>166</sup>Ho, <sup>177</sup>Lu, <sup>186</sup>Re, <sup>188</sup>Re, <sup>211</sup>At, <sup>211</sup>Bi, <sup>212</sup>Bi, <sup>213</sup>Bi and <sup>214</sup>Bi, <sup>103</sup>Pd, <sup>110</sup>Ag, <sup>147</sup>Pm and <sup>207</sup>Bi.
52. (CANCELLED)
53. (CANCELLED)